title: European guidelines for diagnosis and treatment of adenovirus infection in leukemia and stem cell transplantation: summary of ECIL-4 (2011).
abstract: Human adenovirus (HAdV) infections are increasingly recognized as important pathogens in immunocompromised hosts, especially in patients with severely suppressed T-cell function. The 4th European Conference of Infections in Leukemia (ECIL-4) has developed evidence-based guidelines for diagnosis and management of HAdV infections. The risk for HAdV-associated disease is increased in children, and risk factors for HAdV disease are T-cell depletion, unrelated and cord blood hematopoietic stem cell transplantation, graft-versus-host disease grades III-IV, and lymphopenia. The recommended technique for monitoring of high-risk patients is quantitative polymerase chain reaction. Cidofovir is the most used antiviral therapy, although no controlled study has been performed. HAdV-specific T-cell therapy is in development.
authors.affiliation: Department of Pediatrics, Stem Cell Transplantation Unit, St Anna Children's Hospital, Medical University, Vienna, Austria.
authors.forename: S
authors.initials: S
authors.lastname: Matthes-Martin
authors.forename: T
authors.initials: T
authors.lastname: Feuchtinger
authors.forename: P J
authors.initials: PJ
authors.lastname: Shaw
authors.forename: D
authors.initials: D
authors.lastname: Engelhard
authors.forename: H H
authors.initials: HH
authors.lastname: Hirsch
authors.forename: C
authors.initials: C
authors.lastname: Cordonnier
authors.forename: P
authors.initials: P
authors.lastname: Ljungman
mesh_terms: D000258:Adenovirus Infections, Human / Q000175:diagnosis* / Q000209:etiology / Q000628:therapy*; D005060:Europe; D006801:Humans; D007938:Leukemia / Q000150:complications*; D017410:Practice Guidelines as Topic; D033581:Stem Cell Transplantation / Q000009:adverse effects*